Loading clinical trials...
Loading clinical trials...
A Randomized, Parallel-Group Study on the Duration Response of Highly Concentrated On Label Dose (COLD) of BOTOX® Compared to the On Label Dose and Concentration (OLD) in Subjects With Moderate to Severe Dynamic Glabellar Lines
Conditions
Interventions
OnabotulinumtoxinA
Locations
2
United States
Clinical Testing of Beverly Hills
Encino, California, United States
Steve Yoelin MD
Newport Beach, California, United States
Start Date
October 20, 2021
Primary Completion Date
August 1, 2022
Completion Date
August 1, 2022
Last Updated
October 27, 2021
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT04249583
Lead Sponsor
Clinical Testing of Beverly Hills
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions